Article Figures & Tables
Figures
- Fig. 1.
NTN phenotypes in parental and congenic rat strains. (A) Percentage of glomeruli with crescent formation. (B) Macrophage infiltration quantified by the percentage of ED1+ cells per glomerular cross-section. (C) Measurement of proteinuria. ***P<0.001; *P<0.05 between LEW.WCrgn1,2 and LEW rats using oneway ANOVA with Newman-Keuls comparison test. WKY, LEW, LEW.WCrgn1, LEW.WCrgn2 rats, n=6; LEW.WCrgn1,2 rats, n=10, except for proteinuria, where n=9. (D) H&E staining (upper panels) and ED-1 (CD68) immunohistochemistry (lower panels) of glomeruli 10 days after injection with NTS. The H&E stain showed crescentic glomeruli in WKY rats and, for the first time, formation of glomerular crescents in a LEW-derived strain (LEW.WCrgn1,2), whereas LEW rats were resistant to crescent formation. ED-1 immunohistochemistry also showed a significant influx of glomerular macrophages in the LEW.WCrgn1,2 strain.
- Fig. 2.
Tnfα,Nos2 and Mmp12 expression from nephritic glomeruli. (A) Pro-inflammatory cytokine Tumour necrosis factor-α; (B) nitric oxide synthase-2; and (C) matrix metalloproteinase-12 expression measured in nephritic glomeruli 10 days after induction of NTN. Analyses carried out by qRT-PCR. ***P<0.001 between LEW.WCrgn1,2 and LEW rats using one-way ANOVA with Newman-Keuls comparison test. n=4 in all strains.
- Fig. 3.
EAG phenotypes and autoantibody responses in parental (WKY and LEW) and double congenic (LEW.WCrgn1,2) rat strains at day 28. (A) Percentage of glomeruli with crescents. (B) Macrophage infiltration quantified by the percentage of ED1+ cells per glomerular cross-section. (C) Measurement of proteinuria. (D) Serum circulating anti-GBM antibody levels, showing similar serological autoimmunity in all three strains. (E) Quantification of deposited anti-GBM antibody (graded 0 to 3+ intensity) in each rat strain assessed by direct immunofluorescence (IF) for anti-rat immunoglobulins. (A–E) Statistically significant differences in mean values between the LEW.WCrgn1,2 strain and LEW strain compared using a one-way ANOVA with Newman-Keuls comparison test. ns: non-significant. WKY and LEW rats, n=6; LEW.WCrgn1,2 rats, n=10. (F) Representative direct immunofluorescence images showing pattern and intensity of anti-GBM antibody deposition in glomeruli in each rat strain.
- Fig. 4.
Macrophage activation assays in BMDMs in parental (WKY and LEW) and double congenic (LEW.WCrgn1,2) rat strains. (A) Production of superoxide assessed by chemiluminescence over 90 minutes, following addition of PMA (1 μM) (n=3 in all strains). (B,C) Fc-receptor-mediated phagocytic activity of BMDMs assessed by incubating WKY, LEW and LEW.WCrgn1,2 BMDMs with beads opsonised with rabbit anti-BSA IgG, or unopsonised for 30 minutes. Cells were then fixed and beads in 100 BMDMs were counted (n=4 in all strains). *P<0.05 between LEW.WCrgn1,2 and LEW rats using one-way ANOVA with Newman-Keuls comparison test.
- Fig. 5.
Gene expression profiles in BMDMs in parental (WKY and LEW) and double congenic (LEW.WCrgn1,2) rat strains. (A) Pro-inflammatory cytokine Nos2; (B) anti-inflammatory cytokine Il10; (C) Lilrb3l; (D) Nov and (E) Arg1 expression in LPS-stimulated BMDMs (except Nov, for which BMDMs in basal state). Expression analyses were carried out by qRT-PCR. ***P<0.001; **P<0.01; P was non-significant (ns) between LEW.WCrgn1,2 and LEW rats using one-way ANOVA with Newman-Keuls comparison test. n=4 biological rats per strain with three technical replicates per rat. BMDMs were untreated (basal) or stimulated with 100 ng LPS for 4 hours.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Subject collections
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief
We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’
Did you know DMM Conference Travel Grants can be used for online meetings?
With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.
The current application round closes on 8 February 2021 – find out more.
Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart
Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.
C. elegans as a disease model
A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.
Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.
Interview – Kim Landry-Truchon and Nicolas Houde
In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.